233 related articles for article (PubMed ID: 31020663)
1. Piperacillin/tazobactam vs carbapenems for patients with bacterial infection: Protocol for a systematic review.
Petersen MW; Perner A; Sjövall F; Jonsson AB; Steensen M; Andersen JS; Achiam MP; Frimodt-Møller N; Møller MH
Acta Anaesthesiol Scand; 2019 Aug; 63(7):973-978. PubMed ID: 31020663
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
[TBL] [Abstract][Full Text] [Related]
3. Piperacillin/tazobactam versus carbapenems in patients with severe bacterial infections: A systematic review with meta-analysis.
Munch MW; Granholm A; Jonsson AB; Sjövall F; Helleberg M; Hertz FB; Andersen JS; Steensen M; Achiam MP; Perner A; Møller MH
Acta Anaesthesiol Scand; 2023 Aug; 67(7):853-868. PubMed ID: 36919866
[TBL] [Abstract][Full Text] [Related]
4. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
Harris PN; Peleg AY; Iredell J; Ingram PR; Miyakis S; Stewardson AJ; Rogers BA; McBryde ES; Roberts JA; Lipman J; Athan E; Paul SK; Baker P; Harris-Brown T; Paterson DL
Trials; 2015 Jan; 16():24. PubMed ID: 25623485
[TBL] [Abstract][Full Text] [Related]
5. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
[TBL] [Abstract][Full Text] [Related]
6. Impact of a hospital sepsis management protocol on the selection of empirical antibiotics in infectious disease consultations.
Özden A; Dalgıç B; Demir M; Hazırolan G; Uzun Ö; Metan G
J Chemother; 2024 May; 36(3):190-197. PubMed ID: 38131316
[TBL] [Abstract][Full Text] [Related]
7. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.
Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA
Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120
[TBL] [Abstract][Full Text] [Related]
9. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing
Benanti GE; Brown ART; Shigle TL; Tarrand JJ; Bhatti MM; McDaneld PM; Shelburne SA; Aitken SL
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509935
[TBL] [Abstract][Full Text] [Related]
10. Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study.
Al Muqati H; Al Turaiki A; Al Dhahri F; Al Enazi H; Althemery A
J Infect Public Health; 2021 Mar; 14(3):306-310. PubMed ID: 33618274
[TBL] [Abstract][Full Text] [Related]
11. Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study.
Rando E; Salvati F; Sangiorgi F; Catania F; Leone E; Oliva A; Di Gennaro F; Fiori B; Cancelli F; Figliomeni S; Bobbio F; Sacco F; Bavaro DF; Diella L; Belati A; Saracino A; Mastroianni CM; Fantoni M; Murri R
J Antimicrob Chemother; 2024 Feb; 79(2):453-461. PubMed ID: 38169441
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Abdel Fattah M; Haquin J; Macgowan A; Grier S; Gibbs J; Chazan B; Yanovskay A; Ben Ami R; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodriguez-Bano J; Morales I; Oliver A; Ruiz De Gopegui E; Cano A; Machuca I; Gozalo-Marguello M; Martinez Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
Clin Infect Dis; 2020 May; 70(11):2270-2280. PubMed ID: 31323088
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
[TBL] [Abstract][Full Text] [Related]
15. [Piperacillin/tazobactam--Tazocin. A penicillin-based alternative to 3rd generation cephalosporins and carbapenems].
Schønning K; Tvede M
Ugeskr Laeger; 2002 May; 164(20):2606-10. PubMed ID: 12043402
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a Carbapenem-Saving Strategy Using Empirical Combination Regimen of Piperacillin-Tazobactam and Amikacin in Hemato-Oncology Patients.
Ko JH; Kim SH; Kang CI; Cho SY; Lee NY; Chung DR; Peck KR; Song JH
J Korean Med Sci; 2019 Jan; 34(2):e17. PubMed ID: 30636947
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
Falagas ME; Tansarli GS; Ikawa K; Vardakas KZ
Clin Infect Dis; 2013 Jan; 56(2):272-82. PubMed ID: 23074314
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
Maillard A; Delory T; Bernier J; Villa A; Chaibi K; Escaut L; Contejean A; Bercot B; Robert J; El Alaoui F; Tankovic J; Poupet H; Cuzon G; Lafaurie M; Surgers L; Joseph A; Paccoud O; Molina JM; Bleibtreu A;
Int J Antimicrob Agents; 2023 Jul; 62(1):106809. PubMed ID: 37028731
[TBL] [Abstract][Full Text] [Related]
19. Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms.
Schuetz AN; Reyes S; Tamma PD
J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29237787
[TBL] [Abstract][Full Text] [Related]
20. Results of the effectiveness of two piperacillin-tazobactam molecules in the real world.
Machado-Alba JE; Gaviria-Mendoza A; Machado-Duque ME
Int J Infect Dis; 2018 Nov; 76():91-96. PubMed ID: 30244077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
